• Home
  • Changchun GeneScience Pharmaceutical Co.,Ltd.
16-18
Jun
2026
CPHI & PMEC China 2026
Shanghai New International Expo Center
W4F16
Book a meeting
25-27
Aug
2026
CPHI Korea 2026
COEX, Seoul, Korea
T01
Book a meeting
6-8
Oct
2026
CPHI Milan 2026
Fiera Milano, Italy
12F53
Book a meeting

Changchun GeneScience Pharmaceutical Co.,Ltd.

  • Product list
About Changchun GeneScience Pharmaceutical Co.,Ltd.

GenSci is focused on R&D, manufacturing, commercialization and export of products in the fields of children growth, women’s health, wound healing, anti-aging, oncology, etc, GenSci has successfully launched a series of products including Somatropin, Follitropin, Molgramostim gel, Triptorelin, etc. GenSci is traveling on the road of innovative medicines and will bring new hopes to patients…

Read more Show less
Certifications
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI & PMEC China 2026

    CPHI & PMEC China 2026

    Shanghai New International Expo Center
    16 Jun 2026 - 18 Jun 2026
  • CPHI Korea 2026

    CPHI Korea 2026

    COEX, Seoul, Korea
    25 Aug 2026 - 27 Aug 2026
  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
  • Country/Region:
    China
  • On CPHI since:
    2023
  • Certificates:
    1
  • Employees:
    5000+
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Contact info
  • +86-431-85195060
  • No. 1718 Yueda Road, Changchun, 130012, Changchun City, China
Show contact info Hide contact info

Products from Changchun GeneScience Pharmaceutical Co.,Ltd. (5)

Changchun GeneScience Pharmaceutical Co.,Ltd. Resources (2)

  • News Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 Months

    Recently, the National Medical Products Administration (NMPA) of China announced that Gensci's Class 1 innovative drug Jin Beixin Firsekibart has received approval. This drug is indicated for gouty arthritis (GA) treatment in adult patients for whom NSAIDs and/or colchicine are contraindicated, not tolerated, or ineffective and for whom repeated courses of corticosteroids are not suitable. Leveraging its clinical advantages of sustained symptom control, rapid onset of action and a favorable safety profile, Jin Beixin Firsekibart is expected to be China’s best-selling drug to address the unmet need in the treatment of autoimmune diseases. 
    14 Jul 2025
  • Product List

    Brochure Product List

    GenSci's Product List